138 related articles for article (PubMed ID: 8422595)
1. Edatrexate, an antifolate with antitumor activity: a review.
Grant SC; Kris MG; Young CW; Sirotnak FM
Cancer Invest; 1993; 11(1):36-45. PubMed ID: 8422595
[TBL] [Abstract][Full Text] [Related]
2. Edatrexate studies in non-small cell lung cancer.
Gralla RJ
Lung Cancer; 1995 Apr; 12 Suppl 1():S187-91. PubMed ID: 7551928
[TBL] [Abstract][Full Text] [Related]
3. Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy.
Lee JS; Murphy WK; Shirinian MH; Pang A; Hong WK
Cancer Chemother Pharmacol; 1991; 28(3):199-204. PubMed ID: 1649705
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy.
Edelman MJ; Gandara DR; Perez EA; Lau D; Lauder I; Turrell C; Uhrich M; Meyers F
Invest New Drugs; 1998; 16(1):69-75. PubMed ID: 9740546
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma.
Pazdur R; Moore DF; Bready B; Giannone L; Maldonado A; Lin YG; Fueger RH; Winn RJ; Levin B
Ann Oncol; 1994 Sep; 5(7):646-8. PubMed ID: 7527654
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer.
Schornagel JH; van der Vegt S; Verweij J; de Graeff A; Dullemond-Westland A; van Deijk WA; ten Bokkel Huinink WW
Ann Oncol; 1992 Jul; 3(7):549-52. PubMed ID: 1498076
[TBL] [Abstract][Full Text] [Related]
9. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
Kindler HL; Belani CP; Herndon JE; Vogelzang NJ; Suzuki Y; Green MR
Cancer; 1999 Nov; 86(10):1985-91. PubMed ID: 10570422
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer.
Souhami RL; Rudd RM; Spiro SG; Allen R; Lamond P; Harper PG
Cancer Chemother Pharmacol; 1992; 30(6):465-8. PubMed ID: 1327568
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis.
Perez EA; Hack FM; Webber LM; Chou TC
Cancer Chemother Pharmacol; 1993; 33(3):245-50. PubMed ID: 8269606
[TBL] [Abstract][Full Text] [Related]
12. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.
Sirotnak FM; DeGraw JI; Colwell WT; Piper JR
Cancer Chemother Pharmacol; 1998; 42(4):313-8. PubMed ID: 9744777
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124).
Meyers FJ; Lew D; Lara PN; Williamson S; Marshall E; Balcerzak SP; Rivkin SE; Samlowski W; Crawford ED
Invest New Drugs; 1998-1999; 16(4):347-51. PubMed ID: 10426670
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck.
Huber MH; Dimery IW; Benner SE; Lippman SM; Shirinian M; Esparaz B; Frenning D; Guillory-Perez C; Hong WK
Invest New Drugs; 1994; 12(4):327-31. PubMed ID: 7775135
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.
Rigas JR; Kris MG; Miller VA; Pisters KM; Heelan RT; Grant SC; Fennelly DW; Chou TC; Sirotnak FM
Ann Oncol; 1999 May; 10(5):601-3. PubMed ID: 10416013
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
Vandenberg TA; Pritchard KI; Eisenhauer EA; Trudeau ME; Norris BD; Lopez P; Verma SS; Buckman RA; Muldal A
J Clin Oncol; 1993 Jul; 11(7):1241-4. PubMed ID: 8315420
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.
Gandara DR; Edelman MJ; Crowley JJ; Lau DH; Livingston RB
Cancer Chemother Pharmacol; 1997; 41(1):75-8. PubMed ID: 9443617
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of edatrexate in advanced breast and other cancers.
Kuriakose P; Gandara DR; Perez EA
Cancer Invest; 2002; 20(4):473-9. PubMed ID: 12094542
[TBL] [Abstract][Full Text] [Related]
19. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo.
Aghi M; Kramm CM; Breakefield XO
J Natl Cancer Inst; 1999 Jul; 91(14):1233-41. PubMed ID: 10413425
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
